• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Bioactive Products
    Anti-osteoporosis Compound Library
    A unique collection of 39 Anti-diabetic natural compound library for Anti-diabetic screening
    Catalog No: B556 Anti-osteoporosis Compound Library
    Screening Details
    Size: 1mg/well * 39 Compounds
    2mg/well * 39 Compounds
    Catalog No. Information
    CFN98765 Osthol

    1. Osthol has toxicity, may be used as bio-pesticides.
    2. Osthol has anti-allergic effect.
    3. Osthol may exert the therapeutic effect on fat milk-induced fatty liver in mice, by inhibiting hepatic SREBP-1c/2 mRNA expressions and subsequent modulation of SREBP-1c/2-mediated target genes such as FAS, CYP7A and LDL receptor.
    4. Osthol may exert a therapeutic effect on cardiac hypertrophy in rats, and its mechanisms may be related to the improvement of myocardial oxidative stress and lipid metabolism via regulation of PPARα-mediated target gene expressions.
    5. Osthol treatment attenuates liver steatosis by decreasing de novo liver triglyceride synthesis and had nominal effects on insulin resistance and liver inflammation.
    6. Osthol can inhibit P-388 D1 cells in vivo and induce apoptosis in HeLa cells in vitro in a time- and concentration-dependent manner, and that osthol is good lead compound for developing antitumor drugs.
    7. Osthol has antiosteoporosis activity, it can stimulate the osteoblastic differentiation of rat calvarial osteoblast cultures by the BMP-2/p38MAPK/Runx-2/osterix pathway.
    8. Osthol and curcumin are inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus , reversing the resistance against frontline antibacterial drugs.
    CFN98812 Echinocystic acid

    1. Echinocystic acid displays substantial inhibitory activity on HCV entry.
    2. Echinocystic acid induces apoptosis in HL-60 cells through ROS-independent mitochondrial dysfunction pathway.
    3. Echinocystic acid has a cardioprotective effect in rat models with acute myocardial ischemia induced by isoproterenol and vasopressin.
    4. Orally administered lancemaside A may be metabolized to echinocystic acid, which may be absorbed into the blood and ameliorate memory and learning deficits by inhibiting AChE activity and inducing BDNF and p-CREB expressions.
    5. Echinocystic acid has anti-inflammatory effects, it can concentration-dependently inhibit lipopolysaccharide-induced inducible nitric oxide synthase expression at the protein level .
    6. Echinocystic acid may exert hypolipidemic effect by inhibiting the activity of acyl-CoA:cholesterol acyltransferase (ACAT) and diacylglycerol acyltransferase (DGAT).
    7. Echinocystic acid can prevent reduction of bone mass and strength and improve the cancellous bone structure and biochemical properties in old female ovariectomy (OVX) rats, it may serve as a new candidate or a leading compound for anti-osteoporosis.
    CFN98838 Kaempferol

    1. Kaempferol activates LXR-β and suppresses SREBP-1 to enhance symptoms in metabolic syndrome.
    2. Kaempferol exerts a potent inhibitory effect on in vitro bone resorption.
    3. Kaempferol has anti-inflammatory action, can prevent and treat inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis.
    4. Kaempferol has therapeutic potential for the prevention and treatment of thrombovascular diseases, can enhance relaxations caused by endothelium-derived and exogenous NO as well as those due to endothelium-dependent hyperpolarization.
    5. Kaempferol can inhibit cancer cell invasion through blocking the PKCδ/MAPK/AP-1 cascade and subsequent MMP-9 expression and its activity, may act as a therapeutic potential candidate for cancer metastasis.
    6. Kaempferol is an autophagic enhancer, has a more general protection in Parkinson's disease, can mediate antiapoptotic and antioxidant effects is the enhancement of mitochondrial turnover by autophagy.
    CFN98839 Hesperidin

    1. Hesperidin has antioxidative, anti-inflammatory, vasoprotective,and anticarcinogenic effects.
    2. Hesperidin exerts a protective effect against lung damage induced by intestinal I/R injury in rats by reducing oxidative stress.
    3. Hesperidin shows a potent protective effect against CYP-induced oxidative stress and inflammation leading to hepatotoxicity.
    4. Hesperidin exerts its protective effect against CYP-induced hepatotoxicity through upregulation of hepatic PPARγ expression and abrogation of inflammation and oxidative stress.
    5. Hesperidin has beneficial effects on bone and lipids, can inhibit bone loss in ovariectomized mice (OVX), an animal model of postmenopausal osteoporosis.
    6. Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis.
    CFN98867 Kirenol

    1. Kirenol possesses anti-oxidant, anti-inflammatory, anti-allergic, and anti-arthritic activities.
    2. Kirenol is effective against gram-positive bacteria.
    3. Kirenol may be a potential immunosuppressant for the treatment for rheumatoid arthritis.
    4. Kirenol has significant potential for its discovery as a new lead compound for management of topical pain and inflammation.
    5. Kirenol is capable of inhibiting the differentiation and lipogenesis of 3T3-L1 adipocytes through the activation of the Wnt/β-catenin signaling pathway, suggesting its potential as natural anti-obesity agent.
    6. Kirenol can upregulate nuclear Annexin-1 which interacts with NF-κB to attenuate synovial inflammation of collagen-induced arthritis in rats.
    7. Kirenol can attenuate experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells.
    8. Kirenol possesses antitumor action on human chronic myeloid leukemia K562 cells in vitro, it may have therapeutic potential for the treatment of cancer that deserves further investigation.
    9. Kirenol is a potential candidate target for treating or preventing osteoporosis, it is capable of promoting osteoblast differentiation in MC3T3-E1 cells through activation of the BMP and Wnt/β-catenin signaling pathways.